Navigation Links
InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada
Date:7/30/2014

PISCATAWAY, N.J., July 30, 2014 /PRNewswire/ -- InnoPharma, Inc. today announced the first generic launch of Olanzapine for Injection, 10mg/vial (the generic equivalent of Zyprexa® injection), in Canada.  Olanzapine is indicated for the rapid control of agitation and disturbed behaviors in patients with schizophrenia or bipolar I mania.

As the developer of this generic injectable drug, InnoPharma has entered into an agreement with Sandoz Canada Inc., pursuant to which Sandoz Canada will make, use, sell, market and distribute Olanzapine Injection in Canada.  

Commenting on today's news, Navneet Puri, Ph.D., President and Chief Executive Officer of InnoPharma, stated, "Today's announcement is a key milestone for InnoPharma, as it represents the first international launch of one of our products.  As such, it demonstrates our ability to work successfully with regulatory agencies outside the United States, thereby extending our footprint and opening up additional revenue opportunities. We are pleased to work with our collaborator, Sandoz Canada, on the launch of this important generic drug."

On July 16, 2014, Pfizer Inc. (NYSE: PFE) and InnoPharma announced that they have entered into an agreement under which Pfizer will acquire InnoPharma. The closing of the transaction is subject to U.S. regulatory approval and is expected to occur during the third quarter.

About InnoPharma, Inc.

InnoPharma is a sterile product development company, focused on developing complex generic and innovative products in injectable and ophthalmic dosage forms. The Company has a broad portfolio of products under development, with formulations including solutions, lyophilized, suspensions, emulsions, liposomes, micelles and lipid complexes. InnoPharma's pipeline includes small molecules with solubility and stability challenges, as well as difficult to produce and characterize polypeptides and carbohydrates. The Company has a comprehensive infrastructure for the development of its products in its state of the art R&D facilities in New Jersey, with the capability to handle potent and cytotoxic molecules. More information can be found at www.innopharmainc.com.

Zyprexa® is a registered trademark of Eli Lilly and Company

For Further Information Contact:
John C. Deighan
Chief Financial Officer
InnoPharma, Inc.
(732) 885-2939
jdeighan@innopharmainc.com


'/>"/>
SOURCE InnoPharma, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. InnoPharma, Inc., Announces U.S. FDA Approval of Acetylcysteine Solution, USP, 20% for Inhalation or Oral Administration
2. InnoPharma Inc. Raises $8 Million in Venture Debt
3. Unique Pizza and Subs Announces Asian Distribution Agreement with Larasan Pharmaceutical Corporation
4. PCI Announces Definitive Agreement to Acquire Penn Pharma
5. Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine
6. Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point
7. Pfenex Announces Closing of Initial Public Offering
8. Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences
9. Drew Crawford Announces Launch of PBM365 Media
10. Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results
11. EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... --  The Harrington Discovery Institute at University ... has announced the 2017 recipients of Harrington Scholar-Innovator ... whose research shows promise to advance the standard ... – part of The Harrington Project for Discovery ... medicine: to advance early breakthroughs into the clinical ...
(Date:1/16/2017)... , January 16, 2017 According to the ... Controller, Multi Display , Smart Display, Graphic LCD Controller), Application (Industrial ... 2022", published by MarketsandMakets, the market is expected to grow from USD ... a CAGR of 9.68% between 2016 and 2022. ... ...
(Date:1/16/2017)... 16, 2017 The ... Type (Methyl, Ethyl, Hydroxyethyl, Hydroxypropyl, Carboxymethyl Cellulose), ... Surface Coatings & Paints), Region - Global ... market was valued at USD 4.51 Billion ... USD 6.41 Billion by 2021, at a ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... 2017 , ... Permobil has just completed the acquisition of ... systems has a well-earned reputation for premium quality, with a focus on fit ... in the custom seating business, which enjoys strong demand, and it complements Permobil’s ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... announce their recent partnership with an innovator in the wheelchair accessibility industry, ... motivate their dealer salespeople to sell wheelchair accessible vehicles. With this new incentive ...
(Date:1/16/2017)... ... January 16, 2017 , ... Date aired: January 9, 2017 ... Sharon Kleyne, America’s leading water educator, researcher and advocate welcomed health activist, author, ... Sharon Kleyne Hour Power of Water, Global Climate Change and Your Health on ...
(Date:1/16/2017)... ... January 16, 2017 , ... In ... education and high-level training standards to an international multidisciplinary group of healthcare treatment ... As a way to further its mission at the grassroots level, iaedp launched ...
(Date:1/16/2017)... ... 16, 2017 , ... San Francisco dentist, Dr. Ben Amini , the ... device which is capable of taking digital impressions of teeth and gums. Conventional bite ... CAD CAM restorations , in terms of speed, efficiency and patient comfort. Increasingly, digital ...
Breaking Medicine News(10 mins):